Related Experiment Videos
[Medical treatment of the threat syndrome with heparin. Long-term prospective study]
Annales De Cardiologie Et D'Angeiologie
|May 1, 1983
Insights
This 19-year study found that heparin treatment for threat syndrome resulted in a 33.94% mortality rate. Survivors showed good life expectancy, with many remaining asymptomatic or experiencing manageable cardiac conditions.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Context:
- A 19-year observational study involving 119 patients diagnosed with a threat syndrome.
- Patients received treatment with heparin over an average observation period of 10.15 years.
Purpose:
- To evaluate the long-term efficacy and outcomes of heparin therapy in patients with threat syndrome.
- To assess mortality rates, life expectancy, and the health status of survivors.
Summary:
- The study reported a total mortality of 33.94% and a cumulative annual mortality of 1.79%.
- The life expectancy for patients treated with heparin was comparable to the general population in Argentina.
- Among survivors (60.51%), 45.83% were asymptomatic, while 54.17% exhibited varying degrees of cardiac pathology.
Impact:
- Heparin therapy demonstrates a significant impact on the long-term management of threat syndrome.
- Findings suggest that heparin treatment can lead to favorable life expectancy and a considerable proportion of asymptomatic survivors.
- The study provides valuable data for clinical decision-making regarding heparin use in threat syndrome patients.
Abstract:
A 19-year study of 119 patients stricken with a threat syndrome and treated with heparin is presented. The average observation period is 10.15 years. The total mortality was 33.94 per cent. The cumulative annual mortality was 1.79 per cent. The life expectancy for treated patients was identical to that of the general population in Argentina. The survivors (60.51% of the cases) were either asymptomatic (45.83%) or presented varying cardiac pathology (54.17%).